Novo Nordisk has inaugurated its new pilot plant for
biopharmaceutical products in Denmark in its latest move to expand
its presence in biopharmaceuticals.
De Novo Pharmaceuticals says it has refocused its business from
in-house drug discovery to commercialisation of its proprietary
in silico drug discovery platforms, halving its workforce in
the process.
Novo Nordisk has sent out the first batch of bulk insulin from a
new facility at its site in Kalundborg, Denmark, that is producing
more than a third of the world's supply.
